Trump’s FDA Reform Agenda: Patient-Focused Approvals
A posting on the transition website takes a much milder tone than the GOP platform issued over the summer.
You may also be interested in...
Top 16 From '16: Pink Sheet's Most Popular Stories
Big developments, key biopharma trends, and other topics that most intrigued and impacted our readers in 2016.
Woodcock Tries To Calm US FDA Staff Fears About Trump
CDER Director's' video advises focusing on the work and "keeping our heads down."
Trump’s Rx For The Drug Industry: Take Two And Have No Idea What Will Happen In The Morning
To call the incoming US president unpredictable would be an understatement, but that doesn’t mean that industry shouldn’t know what to expect.